Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells.
D017209:Apoptosis; D016203:CDC2 Protein Kinase; D045744:Cell Line, Tumor; D019925:Cyclin A / Q000032:analysis; D019926:Cyclin B / Q000032:analysis; D056744:Cyclin B1; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000502:physiology; D018844:Cyclin-Dependent Kinases; D004247:DNA / Q000096:biosynthesis; D004249:DNA Damage; D004261:DNA Replication / Q000187:drug effects*; D019008:Drug Resistance, Neoplasm; D016193:G1 Phase / Q000187:drug effects; D016195:G2 Phase / Q000187:drug effects; D045325:HCT116 Cells; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D010879:Piperazines / Q000494:pharmacology*; D011123:Polyploidy; D016159:Tumor Suppressor Protein p53 / Q000502:physiology
C534699:CCNB1 protein, human; C493956:CDKN1A protein, human; D019925:Cyclin A; D019926:Cyclin B; D056744:Cyclin B1; D050759:Cyclin-Dependent Kinase Inhibitor p21; D007093:Imidazoles; D010879:Piperazines; D016159:Tumor Suppressor Protein p53; C482205:nutlin 3; D004247:DNA; D016203:CDC2 Protein Kinase; C528899:CDK1 protein, human; D018844:Cyclin-Dependent Kinases